Literature DB >> 22441786

Quality of life and economic costs associated with postthrombotic syndrome.

Sumesh Kachroo1, Dylan Boyd, Brahim K Bookhart, Joyce LaMori, Jeff R Schein, David J Rosenberg, Matthew W Reynolds.   

Abstract

PURPOSE: Published evidence on quality-of-life (QOL) outcomes and health care costs in patients with postthrombotic syndrome (PTS), a common and difficult-to-diagnose complication of venous thromboembolism (VTE), is reviewed.
SUMMARY: Occurring in as many as 70% of patients with VTE, PTS remains a challenging and costly disorder, partly due to the lack of a standard diagnostic definition and varying classification systems. Searches of Medline and EMBASE identified 12 articles on humanistic and economic outcomes associated with PTS. The results of U.S. and international studies indicate that PTS is a key determinant of long-term QOL among patients with VTE. In one large study, 37% of patients with VTE developed PTS within two years of a diagnosis of deep venous thrombosis (DVT), and 4% developed severe PTS, with the occurrence of PTS linked to clinically relevant declines in measures of physical and mental health. Research indicates that the economic burden of PTS in the United States may be as high as $200 million annually. Recent progress in efforts to develop standard PTS terminology may facilitate the dissemination of clear consensus guidelines to assist in timely PTS detection and optimal care.
CONCLUSION: Appropriate measures to decrease PTS-related burdens may include the prevention of DVT, clear diagnostic criteria for PTS, and an education campaign aimed at increased standardization in the management of DVT. Gaps in the current understanding of the risk factors, diagnostic criteria, preventive strategies, and even treatment modalities for PTS hamper the ability of clinicians to employ measures that could reduce the occurrence of this disorder and the associated morbidity.

Entities:  

Mesh:

Year:  2012        PMID: 22441786     DOI: 10.2146/ajhp110241

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  8 in total

1.  Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.

Authors:  Holly Guy; Vicki Laskier; Mark Fisher; W Richey Neuman; Iwona Bucior; Steven Deitelzweig; Alexander T Cohen
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

Review 2.  Engaging with quality improvement in anticoagulation management.

Authors:  Geoffrey D Barnes; Eva Kline-Rogers
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 3.  Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis.

Authors:  Kelly Comerford Wormer; Ayesha A Jangda; Farah A El Sayed; Katherine I Stewart; Sunni L Mumford; James H Segars
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2018-03-19       Impact factor: 2.435

Review 4.  New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients.

Authors:  Taki Galanis; Geno J Merli
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

5.  Performance of two clinical scales to assess quality of life in patients with post-thrombotic syndrome.

Authors:  Angela Lee; Chu-Shu Gu; Suresh Vedantham; Clive Kearon; Mark Blostein; Susan R Kahn
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2021-02-04

6.  A Systematic Review and Meta-Analysis of 12-Month Patency After Intervention for Iliofemoral Obstruction Using Dedicated or Non-Dedicated Venous Stents.

Authors:  Ghulam M Majeed; Krishan Lodhia; Jemima Carter; Jack Kingdon; Rachael I Morris; Adam Gwozdz; Athanasios Saratzis; Prakash Saha
Journal:  J Endovasc Ther       Date:  2021-11-10       Impact factor: 3.089

7.  Patient-Completed Caprini Risk Score for Venous Thromboembolism Risk Assessment: Developed and Validated from 1,017 Medical and Surgical Patients.

Authors:  Zhu Zhang; Yifan Wu; Qingxia Liu; Fen Dong; Wenyi Pang; Kaiyuan Zhe; Jun Wan; Wanmu Xie; Wei Wang; Peiran Yang; Aihua Sun; Zhenguo Zhai
Journal:  TH Open       Date:  2022-07-21

8.  New and known predictors of the postthrombotic syndrome: A subanalysis of the ATTRACT trial.

Authors:  Félix Rinfret; Chu-Shu Gu; Suresh Vedantham; Susan R Kahn
Journal:  Res Pract Thromb Haemost       Date:  2022-08-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.